Table 1.
Clinicopathologic characteristics of ILC in this study
| |
|
EZH2 expression
N
(%) |
P
|
|||
|---|---|---|---|---|---|---|
| Total N (%) | 0% to 5% | 5% to 25% | 25% to 50% | >50% | ||
| Age at diagnosis |
|
|
|
|
|
0.255 |
| <50 |
28 (57.1) |
3 (37.5) |
6 (75.0) |
2 (33.3) |
17 (63.0) |
|
| ≤50 |
21 (42.9) |
5 (62.5) |
2 (25.0) |
4 (66.7) |
10 (37.0) |
|
| Menstrual status |
|
|
|
|
|
0.472 |
| Premenopausal |
27 (55.1) |
4 (50.0) |
6 (75.0) |
2 (33.3) |
15 (55.6) |
|
| Postmenopausal |
22 (44.9) |
4 (50.0) |
2 (25.0) |
4 (66.7) |
12 (44.4) |
|
| Body mass index |
|
|
|
|
|
0.647 |
| Underweight (<20) |
3 (6.1) |
1 (12.5) |
0 (0) |
1 (16.7) |
1 (3.7) |
|
| Normal (≥20, <25) |
29 (59.2) |
4 (50.0) |
6 (75.0) |
2 (33.3) |
17 (63.0) |
|
| Overweight (≥25) |
17 (34.7) |
3 (37.5) |
2 (25.0) |
3 (50.0) |
9 (33.3) |
|
| Side of primary tumor |
|
|
|
|
|
0.587 |
| Left |
25 (51.0) |
5 (62.5) |
4 (50.0) |
4 (66.7) |
12 (44.4) |
|
| Right |
21 (42.9) |
3 (37.5) |
3 (37.5) |
1 (16.7) |
14 (51.9) |
|
| Bilateral |
3 (6.1) |
0 (0) |
1 (12.5) |
1 (16.7) |
1 (3.7) |
|
| Multifocality |
|
|
|
|
|
0.981 |
| Monofocal |
38 (77.6) |
6 (75.0) |
6 (75.0) |
5 (83.3) |
21 (77.8) |
|
| Multifocal |
11 (22.4) |
2 (25.0) |
2 (25.0) |
1 (16.7) |
6 (22.2) |
|
| T stage |
|
|
|
|
|
0.770 |
| T1 |
22 (44.9) |
4 (50.0) |
5 (62.5) |
2 (33.3) |
11 (40.7) |
|
| T2 |
23 (46.9) |
3 (37.5) |
3 (37.5) |
4 (66.7) |
13 (48.1) |
|
| T3 |
4 (8.2) |
1 (12.5) |
0 (0) |
0 (0) |
3 (11.1) |
|
| Lymph node metastasis |
|
|
|
|
|
0.403 |
| N0 |
28 (57.1) |
6 (75.0) |
6 (75.0) |
4 (66.7) |
12 (44.4) |
|
| N1 |
8 (16.3) |
1 (12.5) |
2 (25.0) |
0 (0) |
5 (18.5) |
|
| N2 |
4 (8.2) |
1 (12.5) |
0 (0) |
0 (0) |
3 (11.1) |
|
| N3 |
9 (18.4) |
0 (0) |
0 (0) |
2 (33.3) |
7 (25.9) |
|
| Nuclear grade |
|
|
|
|
|
0.025 |
| 1 |
7 (14.3) |
4 (50.0) |
2 (25.0) |
0 (0) |
1 (3.7) |
|
| 2 |
32 (65.3) |
4 (50.0) |
5 (62.5) |
5 (83.3) |
18 (66.7) |
|
| 3 |
10 (20.4) |
0 (0) |
1 (12.5) |
1 (16.7) |
8 (29.6) |
|
| Estrogen receptor status |
|
|
|
|
|
0.629 |
| Negative |
13 (26.5) |
1 (12.5) |
3 (37.5) |
1 (16.7) |
8 (29.6) |
|
| Positive |
36 (73.5) |
7 (87.5) |
5 (62.5) |
5 (83.3) |
19 (70.4) |
|
| Progesterone receptor status |
|
|
|
|
|
0.615 |
| Negative |
10 (20.4) |
2 (25.0) |
2 (25.0) |
0 (0) |
6 (22.2) |
|
| Positive |
39 (79.6) |
6 (75.0) |
6 (75.0) |
6 (100.0) |
21 (77.8) |
|
| Cerb-B2 status |
|
|
|
|
|
0.410 |
| Negative |
39 (79.6) |
5 (62.5) |
7 (87.5) |
4 (66.7) |
23 (85.2) |
|
| Positive |
10 (20.4) |
3 (37.5) |
1 (12.5) |
2 (33.3) |
4 (14.8) |
|
| p53 |
|
|
|
|
|
0.093 |
| Negative |
37 (75.5) |
4 (50.0) |
5 (62.5) |
4 (66.7) |
24 (88.9) |
|
| Positive | 12 (24.5) | 4 (50.0) | 3 (37.5) | 2 (33.3) | 3 (11.1) | |